Clinical trial NCT05359328: RDS MultiSense® SpO2 Validation Study
Official title: RDS MultiSense® SpO2 Validation Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoxia
Keywords: Hypoxia
Pulse Oximetry
SpO2
Remote Monitoring
Connected device
Real-time monitoring
Lead sponsor: Rhythm Diagnostic Systems
Sponsor class: INDUSTRY
First posted: 2022-05-03
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this clinical study is to validate the oxygen saturation (SpO2) accuracy of the RDS MultiSense® Pulse Oximetry during non-motion conditions over the range of 70-100% arterial oxygen saturation (SaO2) as compared to arterial blood samples assessed by measuring carbon monoxide (CO) bound to hemoglobin by CO-Oximetry. Additionally, data will be collected for heart rate accuracy as compared to reference ECG. The end goal is to provide supporting documentation for the SpO2 and heart rate accuracy validation for RDS MultiSense® Pulse Oximetry.

A minimum of 10 healthy adult male and female participants, ranging in age and pigmentation from light to dark, will be enrolled in the study to meet the study design requirements defined by International Organization for Standardization ISO 80601-2-61:2017: corrected version 2018-02 and by the FDA's Guidance for Pulse Oximeters (March 4, 2013). The participants will have an arterial catheter placed in the radial artery to allow for simultaneous blood samples during stable plateaus of induced hypoxic levels.

The investigational device will be placed on the placed on the thorax of the participants (patch on the upper back and external electrode on the right pectoral) per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.


Eligibility criteria: Inclusion Criteria:

* 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either
* Participant must have the ability to understand and provide written informed consent
* Participant is 18 to 50 years of age
* Participant must be willing and able to comply with study procedures and duration
* Participant is a non-smoker or who has not smoked within 2 days prior to the study

Exclusion Criteria:

* Participant is considered as being morbidly obese (defined as BMI \>39.5)
* Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites, tattoo, extensive moles, or freckles in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized.)
* Female participants that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the participant is known to be not of child-bearing potential).
* Smoker participants who have refrained will be screened for Carboxyhemoglobin (COHb) levels \>3% as assessed with a reference devie (Masimo Radical 7)
* Participants with known respiratory conditions (self-reported)
* Participants with known heart or cardiovascular conditions (self-reported, except for blood pressure and ECG review)
* Self-reported health conditions as identified in the Health Assessment Form (self-reported)
* Participants with known clotting disorders (self-reported)
* Participants with severe contact allergies to standard adhesives, silicon, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
* Participants with severe allergies to iodine (only applicable if iodine is used)
* Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
* Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio \< 0.4)
* Unwillingness or inability to remove colored nail polish from test digits.
* Unwillingness to have chest or other test sites shaved
* Other known health condition, should be considered upon disclosure in health assessment form

Primary outcomes:
measure: Validation of SpO2 accuracy performance of RDS MultiSense® Pulse Oximeter by comparison to CO-Oximeter
timeFrame: From beginning to end of controled hypoxia, up to 2 hours
Secondary outcomes:
measure: Evaluation of heart rate accuracy performance of RDS MultiSense® by comparison to ECG-derived heart rate
timeFrame: From beginning to end of monitoring, up to 2 hours
Other outcomes:
Locations:
city: Louisville
country: United States
facility: Clinimark LLC
state: Colorado
Study officials:
References: